Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 6/20 | 0.77 |
| ▸ | JAK1 | P23458 | 6/20 | 0.77 |
| ▸ | TYK2 | P29597 | 5/20 | 0.77 |
| ▸ | JAK3 | P52333 | 4/20 | 0.77 |
| ▸ | IRAK4 | Q9NWZ3 | 7/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11027852 | 1.00 | JAK2 (0.77) | JAK2JAK1TYK2JAK3IRAK4 | |
| SCHEMBL944472 | 0.89 | JAK2 (0.67) | JAK2JAK1TYK2JAK3IRAK4 | |
| SCHEMBL11025625 | 0.89 | JAK2 (0.67) | JAK2JAK1TYK2JAK3IRAK4 | |
| SCHEMBL30053175 | 0.89 | JAK2 (0.67) | JAK2JAK1TYK2JAK3IRAK4 | |
| SCHEMBL11029149 | 0.88 | JAK2 (0.74) | JAK2JAK1TYK2JAK3IRAK4 | |
| SCHEMBL30051650 | 0.88 | JAK2 (0.74) | JAK2JAK1TYK2JAK3IRAK4 | |
| SCHEMBL11031051 | 0.87 | JAK2 (0.77) | JAK2JAK1TYK2JAK3IRAK4 | |
| SCHEMBL11027949 | 0.87 | JAK2 (1.00) | JAK2JAK1TYK2JAK3IRAK4 | |
| SCHEMBL30051447 | 0.87 | JAK2 (0.77) | JAK2JAK1TYK2JAK3IRAK4 | |
| SCHEMBL11027098 | 0.87 | JAK2 (0.77) | JAK2JAK1TYK2JAK3IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150364-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2024-05-09 | — | — | US | disclosed |
| US-20220389020-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389020-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK1, JAK2, JAK3 | JAK2 2/4885JAK1 1/4885TYK2 5/4885 |
| US-20240150364-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK1, JAK2, JAK3 | JAK2 2/4885JAK1 1/4885TYK2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.